Vitamin D Testing Market to Depict 4.9% CAGR from 2022 to 2029; Soaring Cases of Vitamin D Deficiency to Trigger Investments

The global vitamin D testing market size surged from USD 625.0 million in 2022 to USD 871.7 million by 2029. An uptick in sedentary lifestyles, along with chronic and serious diseases linked with the deficiency of vitamin D, will fuel the demand for testing products. Moreover, growing traction for research and development activities will encourage leading companies to invest in the landscape. Prominently, the adoption of the point-of-care testing kits will redefine the global landscape.

According to the latest research report by Fortune Business Insights™ titled, “Vitamin D Testing Market Size, Share & COVID-19 Impact Analysis, By Product (25-Hydroxy Vitamin D Testing, 1,25-Dihydroxy Vitamin D Testing, and 24,25-Dihydroxy Vitamin D Testing), By Application (Clinical Testing and Research Testing), By End-User (Standalone Clinical Laboratories, Hospitals & Clinics, Others) and Regional Forecast, 2022-2029,” the market stood at USD 600.2 million in 2021. It is anticipated to witness 4.9% CAGR during the forecast period.

Plunge in Routine Tests Due to COVID-19 Pandemic Dented Growth Prospect

A host of industries observed repercussions from the onslaught of the COVID-19 pandemic. To illustrate, DiaSorin S.p.A. witnessed a dip of 25.9% in product sales used in vitamin D tests in 2020 as compared to the preceding year. The pandemic led to a plunge in routine blood tests such as lipid profile and vitamin D tests. However, rising health awareness and the rollout of advanced point of care testing kits have surged the demand for testing kits. The next few years are likely to provide promising opportunities with the increasing inclination for testing kits.

F. Hoffmann-La Roche Introduced Cobas Infinity Edge to Integrate and Manage Point-Of-Care Data

Stakeholders are poised to boost vitamin D testing market share with bullish investments in organic and inorganic strategies. Major companies are poised to emphasize cutting-edge technology to tap into markets. Specifically, in January 2022, F. Hoffmann-La Roche Ltd. launched a cloud-based platform, Cobas Infinity Edge, for managing and integrating point-of-care data available for clinical settings. In March 2020, Thermo Fisher Scientific announced the availability of Cascadion SM Clinical Analyzer for Cascadion SM 25-Hydroxy vitamin D assay to bolster their penetration in the U.S. Robust strategic approaches would continue to gain prominence across emerging and advanced economies.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/vitamin-d-testing-market-100968

Rising Cases of Vitamin D Deficiency to Expedite Investments

Palpable cases of vitamin D deficiency and increasing incidence of Inflammatory Bowel Disease (IBD) and osteoporosis have prompted companies to invest in testing kits. According to an article cited in WebMD LLC in April 2020, the global presence of IBD is reported to be 396 cases per 100,000 persons annually. With a large patient pool suffering from vitamin D deficiency warranting treatment, leading companies are likely to invest in the portfolio. The vitamin D testing market growth will be pronounced with increasing awareness campaigns about the significance of nutrition. Investments in R&D activities will continue to boost the value proposition over the next few years.

Major Companies Emphasize Strategic Approaches to Boost Footfall

Leading companies are poised to invest in R&D activities, product launches, technological advancements, and mergers & acquisitions to boost their presence across untapped areas. Furthermore, leading companies could infuse funds into innovations to gain a competitive edge in the global market.

Notable Industry Development

• April 2021 – DiaSorin S.p.A. and Lumos Diagnostics teamed up to roll out LIAISON IQ, which provides cost-effective POC solutions in under 15 minutes.

List of Companies Profiled in the Report

• F. Hoffmann-La Roche Ltd. (Switzerland)


• DiaSorin S.p.A. (Italy)


•  Abbott (U.S)


• bioMérieux SA (France)


• Siemens Healthcare GmbH (Germany)


• Beckman Coulter, Inc. (U.S)


• Quidel Corporation (U.S)


• Thermo Fisher Scientific Inc. (U.S)


• RECIPE Chemicals + Instruments GmbH (Germany)

Further Report Findings

• In terms of product, the 25-hydroxy vitamin D testing segment will account for a considerable share due to the rising prevalence of vitamin D deficiency.


• Europe market size was valued at USD 215.0 million in 2021 and will grow with increasing approval of point-of-care testing products.


• North America market forecast will be strong due to heightened awareness of vitamin D tests.

Table of Segmentation